INVAHIGH SIGNALOPPORTUNITY10-K

INVA has transformed from a pure-play royalty business to a diversified biopharmaceutical company with multiple drug approvals and substantially improved financial metrics.

The company secured FDA approval for NUZOLVENCE in December 2025 for treating uncomplicated urogenital gonorrhea, adding to its commercial portfolio alongside existing products. INVA's strategic evolution beyond royalties into direct commercialization appears to be generating meaningful financial returns and positioning the company for sustained growth in addressing unmet medical needs.

Comparing 2026-02-25 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

INVA demonstrated robust financial performance with revenue growing substantially year-over-year, while cash and equivalents increased 80.7% to $550.9M and stockholders' equity expanded 69.7% to $1.2B. Current liabilities declined sharply by 78.9% to $49.7M, significantly strengthening the balance sheet. The overall financial picture signals successful execution of the company's transformation strategy, with improved liquidity, reduced leverage, and meaningful revenue expansion supporting its diversified biopharmaceutical platform.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+80.7%
$305.0M→$550.9M

Cash position surged 80.7% — strong cash generation or capital raise providing significant financial cushion.

Current Liabilities
Balance Sheet
-78.9%
$236.1M→$49.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Stockholders Equity
Balance Sheet
+69.7%
$691.2M→$1.2B

Equity base grew 69.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Share Buybacks
Cash Flow
-69.3%
$14.8M→$4.5M

Buyback activity reduced 69.3% — capital being redeployed elsewhere or cash conservation underway.

Revenue
P&L
+62.6%
$133.6M→$217.2M

Strong top-line growth of 62.6% — accelerating demand or successful expansion into new markets.

Current Assets
Balance Sheet
+31.2%
$554.3M→$727.5M

Current assets grew 31.2% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+25.7%
$1.3B→$1.6B

Asset base grew 25.7% — expansion through organic growth, acquisitions, or capital deployment.

Interest Expense
P&L
-24.8%
$22.2M→$16.7M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Inventory
Balance Sheet
+16.2%
$33.7M→$39.2M

Inventory built 16.2% — monitor whether demand supports this build or if write-downs may follow.

Net Interest Income
P&L
+10.2%
$19.1M→$21.1M

Net interest income grew 10.2% — benefiting from rate environment or loan book expansion.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-26
ADDED
On February 13, 2026, there we re 74,073,646 shares of the registrant s Common Stock outstanding.
commercialization and commercially launched in the third quarter of 2025; and NUZOLVENCE (formerly known as zoliflodacin), approved by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.
We also have economic interests in other healthcare companies through our portfolio approach.
Our disciplined focus on deploying capital in areas of significant unmet medical need with high value creation potential has driven a meaningful transformation of our company over the years from a pure-play royalty business to a diversified biopharmaceutical company with a strong, fast-growing, differentiated operating platform and multiple other assets with significant promise.
We believe we are well-positioned to deliver significant long-term shareholder value.
+7 more — sign up free →
REMOVED
On February 14, 2025, there were 62,675,545 shares of the registrant s Common Stock outstanding.
Our commercial and marketed products include GIAPREZA (angiotensin II), approved in the United States ( U.S.
) to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved in the U.S.
for the treatment of complicated intra-abdominal infections in adults.
On May 23, 2023, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the United States Food and Drug Administration ( FDA ) and we commenced commercial sales of XACDURO in the third quarter of 2023.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
ABTHIGHAbbott announced a major strategic acquisition of Exact Sciences Corporation to ...
2026-02-20
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →